[1]
|
Donkor, E.S. (2018) Stroke in the 21st Century: A Snapshot of the Burden, Epidemiology, and Quality of Life. Stroke Research and Treatment, 2018, Article ID: 3238165.
|
[2]
|
GBD 2016 Neurology Collaborators (2019) Global, Regional, and National Burden of Neurological Disorders, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18, 459-480.
|
[3]
|
Röther, J., Ford, G.A. and Thijs, V.N.S. (2013) Thrombolytics in Acute Ischaemic Stroke: Historical Perspective and Future Opportunities. Cerebrovascular Diseases, 35, 313-319. https://doi.org/10.1159/000348705
|
[4]
|
Powers, W.J., Rabinstein, A.A., Ackerson, T., Adeoye, O.M., Bambakidis, N.C., Becker, K., et al. (2018) 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 49, e46-e110. https://doi.org/10.1161/str.0000000000000158
|
[5]
|
Abuelazm, M., Seri, A.R., Awad, A.K., Ahmad, U., Mahmoud, A., Albazee, E., et al. (2022) The Efficacy and Safety of Tenecteplase versus Alteplase for Acute Ischemic Stroke: An Updated Systematic Review, Pairwise, and Network Meta-Analysis of Randomized Controlled Trials. Journal of Thrombosis and Thrombolysis, 55, 322-338. https://doi.org/10.1007/s11239-022-02730-5
|
[6]
|
Bhatia, R., Hill, M.D., Shobha, N., Menon, B., Bal, S., Kochar, P., et al. (2010) Low Rates of Acute Recanalization with Intravenous Recombinant Tissue Plasminogen Activator in Ischemic Stroke: Real-World Experience and a Call for Action. Stroke, 41, 2254-2258. https://doi.org/10.1161/strokeaha.110.592535
|
[7]
|
Emberson, J., Lees, K.R., Lyden, P., Blackwell, L., Albers, G., Bluhmki, E., et al. (2014) Effect of Treatment Delay, Age, and Stroke Severity on the Effects of Intravenous Thrombolysis with Alteplase for Acute Ischaemic Stroke: A Meta-Analysis of Individual Patient Data from Randomised Trials. The Lancet, 384, 1929-1935. https://doi.org/10.1016/s0140-6736(14)60584-5
|
[8]
|
Parsons, M., Spratt, N., Bivard, A., Campbell, B., Chung, K., Miteff, F., et al. (2012) A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke. New England Journal of Medicine, 366, 1099-1107. https://doi.org/10.1056/nejmoa1109842
|
[9]
|
Logallo, N., Kvistad, C.E., Nacu, A., Naess, H., Waje-Andreassen, U., Asmuss, J., et al. (2014) The Norwegian Tenecteplase Stroke Trial (NOR-TEST): Randomised Controlled Trial of Tenecteplase vs. Alteplase in Acute Ischaemic Stroke. BMC Neurology, 14, Article No. 106. https://doi.org/10.1186/1471-2377-14-106
|
[10]
|
Coutts, S.B., Dubuc, V., Mandzia, J., Kenney, C., Demchuk, A.M., Smith, E.E., et al. (2015) Tenecteplase-Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke with Proven Occlusion. Stroke, 46, 769-774. https://doi.org/10.1161/strokeaha.114.008504
|
[11]
|
Li, S., Pan, Y., Wang, Z., Liang, Z., Chen, H., Wang, D., et al. (2021) Safety and Efficacy of Tenecteplase versus Alteplase in Patients with Acute Ischaemic Stroke (TRACE): A Multicentre, Randomised, Open Label, Blinded-Endpoint (PROBE) Controlled Phase II Study. Stroke and Vascular Neurology, 7, 47-53. https://doi.org/10.1136/svn-2021-000978
|
[12]
|
Science News 2022—International Stroke Conference. CHABLIS-T: Tenecteplase Thrombolysis for Stroke up to 24 Hours after Onset with Perfusion Imaging Selection. https://professional.heart.org/en/meetings/international-stroke-conference/science-news-2022#thu
|
[13]
|
Logallo, N., Novotny, V., Assmus, J., Kvistad, C.E., Alteheld, L., Rønning, O.M., et al. (2017) Tenecteplase versus Alteplase for Management of Acute Ischaemic Stroke (NOR-TEST): A Phase 3, Randomised, Open-Label, Blinded Endpoint Trial. The Lancet Neurology, 16, 781-788. https://doi.org/10.1016/s1474-4422(17)30253-3
|
[14]
|
Huang, X., Cheripelli, B.K., Lloyd, S.M., Kalladka, D., Moreton, F.C., Siddiqui, A., et al. (2015) Alteplase versus Tenecteplase for Thrombolysis after Ischaemic Stroke (ATTEST): A Phase 2, Randomised, Open-Label, Blinded Endpoint Study. The Lancet Neurology, 14, 368-376. https://doi.org/10.1016/s1474-4422(15)70017-7
|
[15]
|
Rønning, O.M., Logallo, N., Thommessen, B., Tobro, H., Novotny, V., Kvistad, C.E., et al. (2019) Tenecteplase versus Alteplase between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale. Stroke, 50, 498-500. https://doi.org/10.1161/strokeaha.118.024223
|
[16]
|
Kumar, N., Dhar, N., Kumar, M., Tiwari, A., Desai, I. and Madhaw, G. (2022) Tenecteplase and Alteplase for Thrombolysis of Acute Ischemic Stroke within 4.5 Hours: An Efficacy and Safety Study. Annals of Indian Academy of Neurology, 25, 897-901. https://doi.org/10.4103/aian.aian_1127_21
|
[17]
|
Li, S., Campbell, B.C.V., Schwamm, L.H., Fisher, M., Parsons, M., Li, H., et al. (2021) Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-Ii (TRACE II): Rationale and Design. Stroke and Vascular Neurology, 7, 71-76. https://doi.org/10.1136/svn-2021-001074
|
[18]
|
Campbell, B.C.V., Mitchell, P.J., Churilov, L., Yassi, N., Kleinig, T.J., Dowling, R.J., et al. (2018) Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. New England Journal of Medicine, 378, 1573-1582. https://doi.org/10.1056/nejmoa1716405
|
[19]
|
Burgos, A.M. and Saver, J.L. (2019) Evidence That Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials. Stroke, 50, 2156-2162. https://doi.org/10.1161/strokeaha.119.025080
|
[20]
|
Kheiri, B., Osman, M., Abdalla, A., Haykal, T., Ahmed, S., Hassan, M., et al. (2018) Tenecteplase versus Alteplase for Management of Acute Ischemic Stroke: A Pairwise and Network Meta-Analysis of Randomized Clinical Trials. Journal of Thrombosis and Thrombolysis, 46, 440-450. https://doi.org/10.1007/s11239-018-1721-3
|
[21]
|
Thelengana, A., Radhakrishnan, D.M., Prasad, M., Kumar, A. and Prasad, K. (2018) Tenecteplase versus Alteplase in Acute Ischemic Stroke: Systematic Review and Meta-Analysis. Acta Neurologica Belgica, 119, 359-367. https://doi.org/10.1007/s13760-018-0933-9
|